Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

NCT07311850

Active Not RecruitingPhase 3

Sponsor: Pfizer

Conditions: Obesity and Overweight

Interventions: MET097, Placebo

Countries: United States, Bulgaria, Canada, Czechia, Germany, Poland, Romania, Slovakia

This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* BMI ≥ 30 kg/m2 or BMI ≥ 27.0 kg/m2 to \<30.0 kg/m2 and presence of at least 1 of the following weight- related comorbidities: Hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

Exclusion Criteria:

* Have any form of diabetes
* Have a self-reported body weight change \> 5 kg (11 pounds) within 3 months prior to Screening
* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
* History of chronic pancreatitis or presence of acute pancreatitis within the past 180 days prior to the Screening visit; or active/current, symptomatic gallbladder disease
Locations (170)
  • Scottsdale, Arizona, United States
  • Canoga Park, California, United States
  • Garden Grove, California, United States
  • Riverside, California, United States
  • Rolling Hills, California, United States
  • Englewood, Colorado, United States
  • Hollywood, Florida, United States
  • Longwood, Florida, United States
  • Miami, Florida, United States
  • Oviedo, Florida, United States
  • Tampa, Florida, United States
  • Atlanta, Georgia, United States
  • Savannah, Georgia, United States
  • Gaithersburg, Maryland, United States
  • Chesterfield, Missouri, United States
  • Elkhorn, Nebraska, United States
  • Omaha, Nebraska, United States
  • Papillion, Nebraska, United States
  • Marlton, New Jersey, United States
  • Cary, North Carolina, United States
  • Durham, North Carolina, United States
  • Holly Springs, North Carolina, United States
  • Wilmington, North Carolina, United States
  • Wilmington, North Carolina, United States
  • Portland, Oregon, United States
  • Greenville, South Carolina, United States
  • Mauldin, South Carolina, United States
  • Spartanburg, South Carolina, United States
  • Goodlettsville, Tennessee, United States
  • La Vergne, Tennessee, United States
  • + 140 more on CT.gov